Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 19, 2020 at 11:13 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via The US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to be the first BTK inhibitor for the treatment of immune thrombocytopenia (ITP).

    article source